InnoCan Pharma Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a INNPF research report →
Price Chart
About the company
InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes.
- CEO
- Iris Bincovich
- IPO
- 2020
- Employees
- 11
- HQ
- Calgary, AB, CA
Get TickerSpark's AI analysis on INNPF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
- Market Cap
- $6.30M
- P/E
- -6.60
- PEG
- 0.06
- P/S
- 0.26
- P/B
- 1.29
- EV/EBITDA
- -1.28
- Div Yield
- 0.00%
- Gross Margin
- 90.45%
- Op Margin
- -14.60%
- Net Margin
- -4.02%
- ROE
- -19.37%
- ROIC
- -35.89%
Latest fiscal year · YoY change
- Revenue
- $26.61M-9.6%
- Gross Profit
- $23.93M-8.6%
- Op Income
- $-1,255,000
- Net Income
- $-1,124,000+38.7%
- EPS
- $-0.25+40.5%
- OCF Growth
- +131.3%
- FCF Growth
- +130.1%
- 52W High
- $14.26
- 52W Low
- $1.40
- 50D MA
- $13.01
- 200D MA
- $13.01
- Beta
- -0.22
- RSI (14)
- 19
- Avg Volume
- 395
No earnings-call transcripts are available for INNPF yet.
- Free Float
- 79.6%
- Shares Outstanding
- 4.50M
- Float Shares
- 3.58M
Our INNPF coverage
Recent articles, reports, and earnings notes.
No research on INNPF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate INNPF report →VALITIC™ Expands Retail Industry Visibility Through Shoptalk Fall 2026 in Nashville, USA
prnewswire.com · Sep 29
Innocan Pharma Announces Private Placement of Units
prnewswire.com · Sep 9
Over 100,000 Positive Verified Customer Reviews Reflect Growing Consumer Trust
prnewswire.com · Aug 5
Innocan Pharma Posts Strong Q1 2026 Results*, With Revenue Surging 29.7% to US$6.47M
prnewswire.com · May 27
Innocan Pharma Announces Offering of an Additional Debenture to Tamar Innovest
prnewswire.com · Mar 31
Innocan Pharma Reports 2025 Financial Results, with Revenues at US $26.6M
prnewswire.com · Mar 31
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
prnewswire.com · Feb 27
Innocan Pharma Announces LPT-CBD demonstrates Pain Relief over Placebo-Results from a randomized blinded clinical study in Dogs
prnewswire.com · Feb 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.